Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,196 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,196 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.16. Following the sale, the insider now directly owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, October 22nd, Solomon Moshkevich sold 256 shares of Natera stock. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92.

Natera Trading Up 1.6 %

NTRA stock opened at $126.73 on Thursday. Natera, Inc. has a twelve month low of $37.67 and a twelve month high of $133.54. The stock has a market capitalization of $15.67 billion, a price-to-earnings ratio of -51.73 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The firm’s fifty day simple moving average is $123.31 and its two-hundred day simple moving average is $111.82.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm’s revenue was up 58.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.97) EPS. As a group, analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have commented on NTRA shares. UBS Group decreased their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. BTIG Research lifted their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Sanford C. Bernstein raised their price target on Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Wednesday. The Goldman Sachs Group lifted their price objective on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Finally, Morgan Stanley increased their target price on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $125.69.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently modified their holdings of the business. Itau Unibanco Holding S.A. purchased a new position in Natera during the 2nd quarter valued at $28,000. Quarry LP boosted its stake in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC grew its holdings in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the last quarter. Tobam purchased a new position in Natera in the 2nd quarter worth about $74,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in Natera during the 1st quarter valued at about $83,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.